Table 3 Change of colonisation status during follow-up prevalence (Y-2: 2 years before ETI introduction, Y-1: 1 year before ETI introduction, Y0: at ETI introduction, Y + 1: year following ETI introduction) depending on different patients’ clinical characteristics. Change of colonisation prevalence during follow-up depending on age quartiles at Y0. Change of colonisation prevalence during follow-up depending on ppFEV1 groups according to ppFEV1 at Y0. Change of colonisation prevalence during follow-up for three groups defined by terciles of gain in ppFEV1 under ETI treatment.
From: One year of ETI reduces lung bacterial colonisation in adults with cystic fibrosis
Y-2 N = 194 | Y-1 N = 196 | Y0 N = 198 | Y + 1 N = 179 | p-value1 | ||
|---|---|---|---|---|---|---|
Prevalence of colonisation with at least one bacteria of interest - % (n) | ||||||
Age range (years) | ||||||
18–23 | 98 (49) | 96 (48) | 96 (50) | 81 (39) | p = 0.03 | |
23–28 | 100 (46) | 100 (46) | 100 (46) | 87 (34) | ||
28–34 | 100 (51) | 100 (51) | 100 (51) | 100 (44) | ||
34–60 | 100 (45) | 100 (47) | 98 (46) | 91 (42) | ||
ppFEV1 at Y0 (%) | ||||||
< 30% | 100 (11) | 100 (12) | 100 (12) | 100 (12) | p = 0.06 | |
30–50% | 100 (63) | 100 (63) | 98 (62) | 97 (57) | ||
50–70% | 100 (53) | 100 (53) | 98 (54) | 84 (41) | ||
≥ 70% | 98 (62) | 97 (62) | 98 (63) | 86 (48) | ||
Change in ppFEV1 with ETI (%) | ||||||
0–15% | 100 (63) | 100 (64) | 98 (65) | 88 (51) | p = 0.88 | |
15–20% | 100 (65) | 98 (65) | 98 (65) | 92 (56) | ||
20–35% | 98 (65) | 98 (65) | 98 (65) | 92 (54) | ||
